HF
KALV

HRT Financial’s KalVista Pharmaceuticals KALV Stock Holding History

HRT Financial’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.78M Sell
286,916
-136
-0% -$2.19K 0.01% 909
2025
Q4 		$4.63M Buy
+287,052
New +$3.8M 0.01% 819
2022
Q3 		– Sell
-68,778
Closed -$676K – 3171
2022
Q2 		$676K Buy
+68,778
New +$759K 0.01% 1274
2021
Q4 		– Sell
-27,296
Closed -$476K – 3633
2021
Q3 		$476K Buy
+27,296
New +$553K ﹤0.01% 2039

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HRT Financial's KALV Position: Q1 2026 in Review

HRT Financial reduced its KalVista Pharmaceuticals (KALV) stake by 0.05% in Q1 2026, selling an estimated $2.19K and leaving 286,916 shares worth $5.78M. The position accounts for 0.01% of the portfolio, ranked #909.

HRT Financial first reported a position in KALV in Q3 2021 and has held it in 4 quarters since. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • HRT Financial held 286,916 shares of KalVista Pharmaceuticals worth $5.78M as of Q1 2026.
  • HRT Financial sold 136 KalVista Pharmaceuticals shares in Q1 2026, an estimated $2.19K.
  • KalVista Pharmaceuticals made up 0.01% of HRT Financial's portfolio in Q1 2026, its #909 holding.
  • HRT Financial first reported a position in KalVista Pharmaceuticals in Q3 2021 and has held it in 4 quarters since.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.